Noveome Biotherapeutics, Inc. To Present At The 9th Annual Virtual Neurodegenerative Drug Development Summit

PITTSBURGH--(BUSINESS WIRE)-- Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announced that Larry Brown, Sc.D., Executive Vice President and Chief Scientific Officer at Noveome, will host a live presentation during the 9th Annual Virtual Neurodegenerative Drug Development Summit, entitled, “Exploring Cellular Approaches to Neurodegenerative Drug Discovery.” The live presentation will take place Wednesday, February 24, 2021 at 5:00PM EST.

Dr. Brown will present the evolution of Noveome’s neuroprotection research and development program from “cell therapy to secretome”. His presentation will include neuro-repair data in acute CNS injury and chronic nerve inflammation. The studies examined various routes of administration ranging from direct intracranial, intravenous and intraperitoneal delivery of AMP cells to non-invasive targeted intranasal delivery of Noveome’s proprietary ST266 secretome. The path for translation into the clinical will also be discussed.

About Noveome Biotherapeutics, Inc.

Based in Pittsburgh, Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Noveome has completed a Phase 2 open-label clinical trial that demonstrated the benefit ST266 in healing persistent corneal epithelial defects (PEDs) and is currently planning follow-up clinical studies to further characterize the efficacy and safety of ST266 for the treatment of PEDs. In addition to the Phase 2 trial described above, ST266 is also being evaluated in a Phase 1 open-label clinical trial to establish the safety of ST266 in intranasal transcribriform delivery from nose-to-brain and eye. Noveome has launched a program to test ST266 as a treatment for the severe inflammatory response seen in COVID-19 infection as well as the post-COVID-19 symptoms experienced by many COVID-19 patients. For more information, visit www.noveome.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005171/en/

Media Contact:
Erik Clausen
CG Life for Noveome Biotherapeutics, Inc.
781-608-7091

Source: Noveome Biotherapeutics, Inc.

You May Also Be Interested In

• Komline-Sanderson Acquires Haselden to Expand Food & Beverage Industry Offerings and Reverse Osmosis Platform
• Good Rāz Launches New Taste-Free Vitamin D3 Drops for Daily Defense
• Red River Recognized as a US Best Managed Company